Viatris Inc. (VTRS)
NASDAQ: VTRS · Real-Time Price · USD
10.41
+0.29 (2.87%)
At close: Aug 13, 2025, 4:00 PM
10.65
+0.24 (2.31%)
After-hours: Aug 13, 2025, 7:55 PM EDT
Viatris Revenue
Viatris had revenue of $3.58B in the quarter ending June 30, 2025, a decrease of -5.65%. This brings the company's revenue in the last twelve months to $14.12B, down -7.37% year-over-year. In the year 2024, Viatris had annual revenue of $14.74B, down -4.46%.
Revenue (ttm)
$14.12B
Revenue Growth
-7.37%
P/S Ratio
0.88
Revenue / Employee
$441,116
Employees
32,000
Market Cap
12.14B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 14.74B | -687.60M | -4.46% |
Dec 31, 2023 | 15.43B | -835.80M | -5.14% |
Dec 31, 2022 | 16.26B | -1.62B | -9.08% |
Dec 31, 2021 | 17.89B | 5.94B | 49.73% |
Dec 31, 2020 | 11.95B | 445.50M | 3.87% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
Thermo Fisher Scientific | 43.21B |
VTRS News
- 2 days ago - Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S. - PRNewsWire
- 6 days ago - Viatris Inc. (VTRS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Xanax-maker Viatris beats quarterly profit, revenue estimates; shares rise - Reuters
- 6 days ago - Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance - PRNewsWire
- 8 days ago - Viatris Announces Quarterly Dividend - PRNewsWire
- 8 days ago - Viatris Announces Appointment of David Simmons to the Company's Board of Directors - PRNewsWire
- 12 days ago - Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference - PRNewsWire
- 22 days ago - 10 dividend stocks with yields up to 6.92% and plenty of cash flow for higher payouts - Market Watch